ERBB2 and neoplasm: These mAbs can be used to deliver drugs to the tumor, as in the case of trastuzumab emtansine and trastuzumab deruxtecan [5], but their main application is to interfere with Her2 signaling and induce tumor cell killing by immune cells or the complement system [6,7,8,9].